Magrolimab Archives - Medical Conferences

ENHANCE: Magrolimab does not ameliorate health outcomes in high-risk MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, FL, USA

Trial

Phase 3, ENHANCE

Conference

EHA 2024

Type

Peer-reviewed article

12 August 2024 14:19

Promising results for triplet therapy with magrolimab in AML

Presented By

Prof. Naval Daver, Anderson Cancer Center, TX, USA

Trial

Phase 3, ENHANCE-3

Conference

ASH 2022

Type

Peer-reviewed article

20 February 2023 11:17

Promising frontline triplet regimen for TP53-mutated AML

Presented By

Dr Naval Daver, MD Anderson Cancer Center, TX, USA

Trial

Phase 1/2

Conference

ASH 2021

Type

Peer-reviewed article

4 February 2022 11:49

First-in-class macrophage immune checkpoint inhibitor in AML

Presented By

Dr David Sallman, H. Lee Moffitt Cancer Center and Research Institute, Florida, USA

Trial

Phase 1

Conference

ASH 2020

Type

Peer-reviewed article

18 February 2021 09:11

Magrolimab plus azacitidine: good ORR in MDS/AML

Presented By

Prof. Naval Draver, University of Texas MD Anderson Cancer Centre, USA

Trial

Phase 1

Conference

EHA 2020

Type

Peer-reviewed article

9 September 2020 13:14

Overcoming the “don’t eat me” signal in AML and MDS

Presented By

Dr David Sallman, Moffitt Cancer Center, USA

Trial

5F9005

Conference

EHA 2019

Type

Peer-reviewed article

9 August 2019 20:20